SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart

JACC: Basic to Translational Science

Volumn 4, Issue 1, 2019, Pages 15-26

  Lim, Ven G ^a   Bell, Robert M ^a   Arjun, Sapna ^a   Kolatsi Joannou, Maria ^b   Long, David A ^b   Yellon, Derek M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

cardioprotection; diabetes; ischemia reperfusion injury; myocardial infarction; SGLT2 inhibitor

Indexed keywords

CANAGLIFLOZIN; GLUCOSE; SODIUM GLUCOSE COTRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; HEART INFARCTION; HEART INFARCTION SIZE; HEART PROTECTION; LONG TERM CARE; NONHUMAN; RAT; UPREGULATION;

EID: 85061358820     PISSN: 2452302X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacbts.2018.10.002     Document Type: Article

References (28)

1. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
2. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
3. Pioli, M.R., Ritter, A.M.V., Modolo, R., Unsweetening the heart: possible pleiotropic effects of SGLT2 inhibitors on cardio and cerebrovascular alterations in resistant hypertensive subjects. Am J Hypertens 31 (2018), 274–280.
4. Bell, R.M., Yellon, D.M., SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection. Lancet Diabetes Endocrinol 6 (2018), 435–437.
5. Ahmed, H.M., Khraishah, H., Cho, L., Cardioprotective anti-hyperglycemic medications: a review of clinical trials. Eur Heart J 39 (2018), 2368–2375.
6. Moe, G.W., Marin-Garcia, J., Role of cell death in the progression of heart failure. Heart Fail Rev 21 (2016), 157–167.
7. Devineni, D., Curtin, C.R., Polidori, D., et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol 53 (2013), 601–610.
8. Whittington, H.J., Babu, G.G., Mocanu, M.M., Yellon, D.M., Hausenloy, D.J., The diabetic heart: too sweet for its own good?. Cardiol Res Pract, 2012, 2012, 845698.
9. Andreadou, I., Efentakis, P., Balafas, E., et al. Empagliflozin limits myocardial infarction in vivo and cell death in vitro: role of STAT3, mitochondria, and redox aspects. Front Physiol, 8, 2017, 1077.
10. Mudaliar, S., Alloju, S., Henry, R.R., Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care 39 (2016), 1115–1122.
11. Sack, M.N., Murphy, E., The role of comorbidities in cardioprotection. J Cardiovasc Pharmacol Ther 16 (2011), 267–272.
12. Kuriyama, C., Xu, J.Z., Lee, S.P., et al. Analysis of the effect of canagliflozinon renal glucose reabsorption and progression of hyperglycemia in Zucker diabetic Fatty rats. J Pharmacol Exp Ther 351 (2014), 423–431.
13. Sutherland, F.J., Hearse, D.J., The isolated blood and perfusion fluid perfused heart. Pharmacol Res 41 (2000), 613–627.
14. Atageldiyeva, K., Fujita, Y., Yanagimachi, T., et al. Sodium-glucose cotransporter 2 inhibitor and a low carbohydrate diet affect gluconeogenesis and glycogen content differently in the kidney and the liver of non-diabetic mice. PLoS One, 11, 2016, e0157672.
15. Zhang, J., Wang, Y.T., Miller, J.H., Day, M.M., Munger, J.C., Brookes, P.S., Accumulation of succinate in cardiac ischemia primarily occurs via canonical Krebs cycle activity. Cell Rep 23 (2018), 2617–2628.
16. Baartscheer, A., Schumacher, C.A., Wust, R.C., et al. Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)/H(+) exchanger in rats and rabbits. Diabetologia 60 (2017), 568–573.
17. Uthman, L., Baartscheer, A., Bleijlevens, B., et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation. Diabetologia 61 (2018), 722–726.
18. Avkiran, M., Marber, M.S., Na(+)/H(+) exchange inhibitors for cardioprotective therapy: progress, problems and prospects. J Am Coll Cardiol 39 (2002), 747–753.
19. Klein, H.H., Pich, S., Bohle, R.M., Lindert-Heimberg, S., Nebendahl, K., Na(+)/H(+) exchange inhibitor cariporide attenuates cell injury predominantly during ischemia and not at onset of reperfusion in porcine hearts with low residual blood flow. Circulation 102 (2000), 1977–1982.
20. Hale, S.L., Kloner, R.A., Effect of combined K(ATP) channel activation and Na(+)/H(+) exchange inhibition on infarct size in rabbits. Am J Physiol Heart Circ Physiol 279 (2000), H2673–H2677.
21. Mirkovic, S., Seymour, A.M., Fenning, A., et al. Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. Br J Pharmacol 135 (2002), 961–968.
22. Lee, T.M., Chang, N.C., Lin, S.Z., Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med 104 (2017), 298–310.
23. Hawley, S.A., Ford, R.J., Smith, B.K., et al. The Na+/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes 65 (2016), 2784–2794.
24. Chang, Y.K., Choi, H., Jeong, J.Y., et al. Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS One, 11, 2016, e0158810.
25. Steven, S., Oelze, M., Hanf, A., et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol 13 (2017), 370–385.
26. Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
27. Whittington, H.J., Harding, I., Stephenson, C.I., et al. Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling. Cardiovasc Res 99 (2013), 694–704.
28. Korkmaz-Icoz, S., Lehner, A., Li, S., et al. Mild type 2 diabetes mellitus reduces the susceptibility of the heart to ischemia/reperfusion injury: identification of underlying gene expression changes. J Diabetes Res, 2015, 2015, 396414.